This $.73 Unknown Just Unveiled The Greatest Medical Breakthrough Of The 21st Century - Investing Now Could Have Cashing Out A 4694% Winner! Your $5,000 could blossom into $239,726 - your $10,000 could explode into $479,452 - all before a high
priced buyout by "Big Pharma" turns
the medical world upside down! Below, I'll prove to you why a buyout by Teva, Roche or Johnson & Johnson could be more than a just possibility...
it could be guaranteed! Fellow Investor: What I'm about to tell you about could be the most important medical advance in 80 years. You'd have to travel back to 1928, the year Penicillin was discovered, to find something as monumental as what you're about to see! A5 Laboratories (ticker: AFLB) has perfected a way to make interferon - one of the most vital ingredients in some of today's most important drug therapies - 100 times cheaper and potentially 100 to 1,000 times more potent than any other brand on the market today. But before I get into why this company could could make you rich, let me answer that question in the back of your brain...  | What is an interferon? And why is it so important? Interferons are natural proteins made by your body's white blood cells. They perform many critical and important immune functions that fight many common and deadly diseases...even cancer! Even just a small drop in the number of these important "life defenders" in your body, can lead to searious illnes and even death. This is why these tiny miracles are used in so many life-saving drug therapies in this $9 billion annual business. But what drug companies are using now, is manufactured, toxic, hard to produce, and very expensive. However, A5 Laboratories(AFLB) my #1 bio-pick of 2010, has just revealed their incredible breakthrough that could very well turn the entire medical world on it's head! |  | This astonishing discovery allows A5 Laboratories to create an all-natural, non-toxic, easily produced and inexpensive ultra-specific interferon that could capture 100% of the interferon market... You heard that correctly, 100%! This has never been done before! Now get this, here's the best part (especially for early investors), A5 Laboratories (ticker: AFLB) could sell their groundbreaking interferon to almost every major drug company out there for 1/7th the price, giving them the potential to post profit margins in excess of 93%! And with such a dramatic price drop, thousands of other companies may buy it, because thousands of new applications could be found for it. Soon, the interferon market which stands at $9 billion, could jump to $12 billion, then to $18 billion, or even to $27 billion! A5 Laboratories (AFLB) could easily control this exploding market This isn't pie in the sky here, interferon is a proven and valuable commodity for Big Pharma and is already approved and used in hundreds of drug formulations... Some of them blockbusters with yearly sales in the $Billions! There is no doubt that A5 Laboratories' new interferon (ng-INF), for which they have 3 patents pending and world-wide manufacturing rights, will revolutionize medical treatment, for both humans and animals, as we know it. And... Almost every drug company, every biotech firm, and every university lab will come knocking on A5's door, asking for their superior interferon at 1/7th the price it's at now! I don't have to tell what that means to early share-holders who buy AFLB shares now, while they're between just $.75 and $1.50 now... AFLB already grabbing Big Pharma's attention? The surest way to Billion dollar sales (and gigantic profits for A5 and its shareholders) is to form licensing agreements for established pharmaceutical companies to manufacture their ng-INF. A5 could very well cut a licensing deal with Big Pharma companies, like Pfizer and Merck, to manufacture and add ng-INF to their already blockbuster formulas. Assuming A5's ng-INF makes these products more effective, sales of their top therapies could easily double, as it becomes the "it" drug. If this happens, A5 collects a percentage-of-sales royalty on every new formulation using their interferon formula. But let's think about this... Why would these companies cut a royalty deal with AFLB, when they already have top-selling drugs? Well, one reason is they'll pay a lot less for the interferon. But more importantly... If they don't, their competition could cut a deal with A5 and their superior ng-INF, likely making their product the drug of choice! The "loser's" sales could virtually dry up overnight, while the "winner's" sales could hit $5 billion or more! And if Pfizer or Merck don't want in, Biogen would love to add A5's ng-INF to its products, which could very well quadruple its current $1.7 billion annual sales to $6.8 Billion, while Merck and Pfizer become dust in the wind! Do you see now, why A5 Laboratories is my favorite bio tech pick of 2010? Because, let's face it, one of these giant drug companies almost HAS to buy AFLB out in order to lock in triple or even quadruple profits! I urge you, if you only do one thing today, please read the FREE report on A5 Laboratories by SELECTING HERE. Mark my words, AFLB owns the single greatest breakthrough in drug technology in my lifetime, which is why I'm calling AFLB my top Biotech pick lock of 2010 and beyond!! Don't wait on this one
Go here to read on Happy investing, Tim Fields
Untapped Wealth
IMPORTANT NOTICE AND DISCLAIMER: This featured company sponsored advertising issue of Untapped Wealth does not purport to provide an analysis of any company's financial position, operations or prospects and this is not to be construed as a recommendation by Untapped Wealth or an offer or solicitation to buy or sell any security. A5 Laboratories, (AFLB), the company featured in this issue, appears as paid advertising, paid by Towson Development Ltd. to provide public awareness for AFLB. Towson Development Ltd. has approved and signed off as approved for public dissemination all statements made herein regarding AFLB's history, assets, technologies, current as well as prospective business operations and industry information. Untapped Wealth and Capital Financial Media (CFM) have used outside research and writers using public information to create the advertisement coming from Untapped Wealth about AFLB. Although the information contained in this advertisement is believed to be reliable, Untapped Wealth and CFM makes no warranties as to the accuracy of any of the content herein and accepts no liability for how readers may choose to utilize the content. Readers should perform their own due-diligence, including consulting with a licensed, qualified investment professional or analyst. Further, readers are strongly urged to independently verify all statements made in this advertisement and perform extensive due diligence on this or any other advertised company. Untapped Wealth is not offering securities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. Many states have established rules requiring the approval of a security by a state security administrator. Check with http://www.nasaa.org or call your state se- curity administrator to determine whether a particular security is licensed for sale in your state. Many companies have information filed with state securities regulators and many will supply investors with additional information on request. CFM has received and managed a total production budget of $900,000 for this advertising effort and will retain any amounts over and above the cost of production, copywriting services, mailing and other distribution expenses, as a fee for its services. Untapped Wealth is paid $3,000 as an editorial fee from CFM and also expects to receive new subscriber revenue as a result of this advertising effort. *More information can be received from A5 Laboratories's investor relations firm, or at A5 Laboratories's website www.a5labs.com. Further, specific financial information, filings and disclosures as well as general investor information about publicly traded companies like A5 Laboratories, advice to in- vestors and other investor resources are available at the Securities and Exchange Commission website www.sec.gov and www.nasd.com. Any investment should be made only after con- sulting with a qualified investment advisor and after reviewing the publicly available financial statements of and other information about the company and verifying that the investment is appropriate and suitable. Investing in securities is highly speculative and carries a great deal of risk especially as to new companies with limited operations and no history of earnings. The information contained herein contains forward-looking information within the meaning of section 27a of the Securities Act of 1993, as amended, and section 21e of the Securities Exchange Act of 1934, as amended, including statements regarding expected growth of the featured company. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act, A5 Laboratories notes that statements contained herein that look forward in time, which include everything other than historical information, involve risks and uncertainties that may af- fect the Company's actual results of operations. Factors that could cause actual results to differ include the size and growth of the market, the Company's ability to fund its capital requirements in the near term and in the long term; pricing pressures, technology issues etc. | |
No comments:
Post a Comment